My research centers on quantitative clinical nuclear medical imaging using single-photon emission computed tomography (SPECT)/CT and PET/CT. Separately, each of these imaging modalities has clinical limitations: SPECT images are not quantitative, and planar images cannot be used to precisely calculate radiation dose levels in normal tissue or to assess tumor dosimetry and kinetics. I am working to implement and validate quantitative SPECT/CT imaging by evaluating variability in the standard uptake value (SUV) – the amount of radiation absorbed by a target tissue – a measurement that is used to stage tumors and assess response to therapy.
Currently, I am performing an extended study evaluating the repeatability of SUV measurements and to determine if there is a relationship between SUV variability and tumor site, origin, or size. I am also involved in several research projects using compartmental modeling of dynamic PET to understand the behavior of novel radiotracers in the body. I am particularly interested in determining parameter variability to improve measuring techniques.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jazmin Schwartz discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.